menu
    • menu
    [{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Dogwood Therapeutics \/ Wex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Dogwood Therapeutics \/ Wex Pharmaceuticals"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Dogwood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dogwood Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Dogwood Therapeutics

    Menu

    Dogwood Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dogwood Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Dogwood Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Valacyclovir,Celecoxib

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dogwood’s IMC-2 Improves Long-COVID Fatigue and Sleep in Early Study Results

                            Details : IMC-2 (combination of valacyclovir and celecoxib) is being evaluated as a potential treatment for fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID.

                            Brand Name : IMC-2

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 18, 2024

                            Lead Product(s) : Valacyclovir,Celecoxib

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dogwood Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Dogwood Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : WEX Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Virios Therapeutics And Wex Pharmaceuticals Form Dogwood Therapeutics

                            Details : The combined company will be focused on Halneuron, in Phase 2b for chemotherapy-induced neuropathic pain, IMC-1, poised for Phase 3 for fibromyalgia and IMC-2 to treat Long-COVID sequelae.

                            Brand Name : Halneuron

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : Tetrodotoxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : WEX Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth